Pfizer (PFE) is seeking to sell more than half of its stake or 2.50 billion British pounds ($3.05 billion) worth of shares in Haleon (HLN), multiple news outlets reported Wednesday, citing bookrunner JPMorgan (JPM).
The sale of 700 million shares at 3.57 pounds per share would lower Pfizer's stake in the UK consumer healthcare firm, which makes Sensodyne, Panadol, Centrum, and Advil, to 7.3% from 15%, Reuters reported.
Pfizer, which will continue to be Haleon's largest shareholder after the sale, said in 2023 it would reduce its stake in a "slow and methodical" manner within months, Reuters reported.
Pfizer, JPMorgan, and Haleon did not immediately reply to MT Newswires' requests for comment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。